Moral Universalism: Global Evidence

Last registered on April 13, 2021
View Trial History

Pre-Trial

Trial Information

General Information

Title
Moral Universalism: Global Evidence
RCT ID
AEARCTR-0007525
Initial registration date
April 11, 2021

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
April 13, 2021, 11:31 AM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

Country
United States of America
Region

Primary Investigator

Name
Benjamin Enke
Affiliation
Contact Primary Investigator

Other Primary Investigator(s)

PI Name
Bertil Tungodden
PI Affiliation
NHH Bergene
Contact Investigator
PI Name
Alexander Cappelen
PI Affiliation
NHH Bergene
Contact Investigator

Additional Trial Information

Status
Completed
Start date
2020-02-01
End date
2021-03-31
Keywords
Behavior
Additional Keywords
JEL code(s)
Secondary IDs
Abstract
This study implements a global survey in 60 countries to study heterogeneity in moral universalism. The survey contains three treatments arms. Data-collection is complete but as of today we do not have access to the data, which was collected by Gallup.
External Link(s)

Registration Citation

Citation
Cappelen, Alexander, Benjamin Enke and Bertil Tungodden. 2021. "Moral Universalism: Global Evidence." AEA RCT Registry. April 13. https://doi.org/10.1257/rct.7525-1.0
Sponsors & Partners
Experimental Details

Interventions

Intervention(s)
Intervention Start Date
2020-02-01
Intervention End Date
2021-03-31

Primary Outcomes

Primary Outcomes (end points)
See PDF
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
See PDF
Experimental Design Details
Randomization Method
See PDF
Randomization Unit
See PDF
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
60 countries
Sample size: planned number of observations
60,000 respondents
Sample size (or number of clusters) by treatment arms
30,000 respondents in treatment Baseline, and 15,000 each in treatments Moral and Deserving
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
Supporting Documents and Materials
IRB

Institutional Review Boards (IRBs)

IRB Name
Harvard
IRB Approval Date
2020-01-08
IRB Approval Number
IRB19-1896
Analysis Plan

Analysis Plan Documents

Universalism_PAP.pdf

MD5: 61dba919a4b833830c0c89d77f900821

SHA1: 706191045a3cb6ecffbda0a1ed9a2751acad30f2

Uploaded At: April 11, 2021

Post-Trial

Post Trial Information

Study Withdrawal

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Intervention

Is the intervention completed?
No
Data Collection Complete
Data Publication

Data Publication

Is public data available?
No

Program Files

Program Files
Reports, Papers & Other Materials

Relevant Paper(s)

Reports & Other Materials